Michael Perry
Neurology with Special Qualifications in Child Neurology · Fort Worth, TXNPI 1346364809
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $109,179 of the $161,595 with a category attached, or 67.6%. It is spread thinly across 18 manufacturers, the largest accounting for just 19.3%. Reporting peaked in 2024 at $43,570 and has fallen 55.5% since, to $19,394 in 2025. Among neurology with special qualifications in child neurology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 220 payments — averaging $734.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$31K
- Neurelis, Inc.$30K
- Zogenix Inc.$29K
- UCB SA$29K
- Immedica Pharma US, Inc.$21K
- Azurity Pharmaceuticals, Inc.$6K
- plus $16K from 12 others
Across 190 payments — averaging $4101.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GW Research Limited$460K
- Takeda Pharmaceuticals U.S.A., Inc.$250K
- Zogenix Inc.$37K
- UCB SA$18K
- Neurocrine Biosciences, Inc.$12K
- Immedica Pharma US, Inc.$4K
What the payments were for
- Consulting fees$109,17968%
- Speaking & faculty fees$35,41722%
- Travel & lodging$10,2016%
- Food & beverage$6,7984%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 53 | $31,221 |
| Neurelis, Inc. | 47 | $30,464 |
| Zogenix Inc. | 42 | $29,181 |
| UCB SA | 7 | $28,870 |
| Immedica Pharma US, Inc. | 16 | $20,597 |
| Azurity Pharmaceuticals, Inc. | 2 | $5,610 |
| Jazz Pharmaceuticals Inc. | 19 | $4,385 |
| Eisai Inc. | 6 | $4,010 |
| Greenwich Biosciences, Inc. | 7 | $2,131 |
| Biomarin Pharmaceutical Inc. | 1 | $1,600 |
| Otter Pharmaceuticals, LLC | 1 | $1,338 |
| Biocodex, Inc. | 10 | $1,312 |
| Neuropace, Inc. | 4 | $723 |
| SK Life Science, Inc. | 1 | $57 |
| Channel Medsystems, Inc. | 1 | $47 |
| Livanova USA, Inc. | 1 | $19 |
| Neurocrine Biosciences, Inc. | 1 | $16 |
| Convatec Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fintepla$63,173
- VALTOCO$29,620
- ZTALMY$18,942
- Epidiolex$5,829
- Brineura$1,600
- SYMPAZAN$1,338
- DIACOMIT$947
- RNS System$546
- RNS Neurostimulator Kit$154
How this compares
$161,595 in reported general payments places this provider in the 95th percentile of 193 neurology with special qualifications in child neurology providers in Texas.
See all neurology with special qualifications in child neurology providers in Texas →
Other neurology with special qualifications in child neurology in Fort Worth
- Warren MarksFort Worth$58K
- Stephanie AcordFort Worth$12K
- Dave ShahaniFort Worth$8K
- Cynthia KeatorFort Worth$5K
- Brittney RhemFort Worth$5K
- Roy EltermanDallas$5.9M
- Huda ZoghbiHouston$5.5M
- Diana CastroDenton$343K
- Shade MoodyHouston$194K
- Mary Kay KoenigHouston$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.